tbuckley/cabot-search huggingface dataset:
THE LATERAL-CHAIN THEORY OF IMMUNITY
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Annals of Allergy, Boston
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effects of Ethylene Glycol Monomethyl (EGME) and Monoethyl (EGEE) Ethers on the Immunocompetence of Allogeneic and Syngeneic Mice Bearing L1210 Mouse Leukemia
Authors: David P. Houchens, Artemio A. Ovejera, Richard W. Niemeier
Journal: Environmental Health Perspectives (1984)

The effect of ethylene glycol monomethyl ether (EGME) and ethylene glycol monoethyl ether (EGEE) on cell-mediated immunity was evaluated by an allograft rejection assay. Allogeneic B6C3F1 (C57BL/6 X C3H) mice were given oral doses of 600, 1200, or 2400 mg/kg/administration of EGEE or 300, 600, 1200 mg/kg/administration of EGME on days -12 through -8 or cyclophosphamide (Cy) at 180 mg/kg by the IP route on day -1. Untreated controls were given oral doses of water on days -12 through -8 and -5 through -1. On day 0, the mice were challenged with 1 X 10(2), 3 X 10(3), and 1 X 10(5) or 3 X 10(6) L1210 cells by the IP route. Syngeneic CD2F1 (Balb/c X DBA/2) mice were challenged with 1 X 10(5) L1210 cells on day 0 and were treated on days 1 to 5 and 8 to 12 with the same dosages of EGME and EGEE used for the B6C3F1 mice. Water-treated syngeneic mice died with a median survival time (MST) of 8.0 days. There was no effect on the MST of syngeneic mice treated with either EGME or EGEE, indicating no direct antitumor effect of the compounds. All allogeneic mice receiving either water or Cy and challenged with 3 X 10(6) tumor cells, died with ascites. However, when mice were treated with EGME or EGEE and challenged with 3 X 10(6) tumor cells, no more than one animal per group died. This would indicate that there was a prophylactic action of the compounds or that the immune system was stimulated. Blood smears of allogeneic mice were made for differential counts the last day of drug dosing, the day of death where possible, and on survivors at day 43 post-tumor implantation.(ABSTRACT TRUNCATED AT 250 WORDS)
A Correction
Journal: BMJ (1907)

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ TBE EXETER MEETING.THE route from England to Ireland vl& Fishgiiard, which has recently been opened by the Great Western Railway, is now in active work, and sliould add to the number of Irish medical men attending the annual meeting at Exeter.The steamers which make the passage have been specially built ior the purpose, and betng worked by turbine enginEs are free from vibration, and travel so fast that the sta passage lasts considerably 1es3 shan three hours The route.mort- over, affords a direct connexion with Exeter from Dublin, Galway, Athione, IKildare, Killalne, Kilkenny, Limerick, Tipperary, Clonmel, Cork, and Killarney.Far residents in -Lsndon and-other-great centres the journey to Exeter Is, of course, very easy, as the Great Western now has expresses which complete the journey from London In thrae hours, and from North and Soutlh Wales, Liverpool, Manchester, Birmingham, and the Midlands In generai with corresponding rapidity."HOSPITAL ABUSE."
Textbook of Medicine by Various Authors.
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
index to advertisers
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Relationship between driver's license renewal policies and fatal crashes involving drivers 70 years or older
Authors: D. T. Levy
Journal: JAMA (1995)

<h3>Objective.</h3> —To assess the relationship between state driver's license renewal policies and fatal crashes involving drivers aged 70 years or older (seniors). <h3>Design and Analysis.</h3> —Poisson regression methods were used to isolate the relationship between different state policies mandating vision tests, knowledge tests, or road tests for driver's license renewal and fatal crashes involving senior drivers. The analysis controlled for differences among states, other than their renewal policies, likely to influence senior motor vehicle crashes. <h3>Setting.</h3> —United States, 1985 through 1989. <h3>Participants.</h3> —All fatal crashes identified in the National Highway Traffic Safety Administration Fatal Accident Reporting System involving at least one driver aged 70 years or older. <h3>Main Outcome Measure.</h3> —The number of fatal crashes per state in which at least one of the drivers was aged 70 years or older. When a single fatal crash involved more than one senior driver, each was included. <h3>Results.</h3> —State-mandated tests of visual acuity, adjusted for license renewal period, were associated with lower fatal crash risk for senior drivers (relative risk, 0.93; 95% confidence interval, 0.89 to 0.97). Knowledge tests, when added to vision tests and applied only to seniors, provided a nonsignificant reduction in the senior fatal crash risk (relative risk, 0.91; 95% confidence interval, 0.79 to 1.05). <h3>Conclusion.</h3> —Tests of vision and knowledge for senior drivers at license renewal merit further attention as a means of improving senior traffic safety. (<i>JAMA</i>. 1995;274:1026-1030)
Effectiveness of home based early intervention on children's BMI at age 2: randomised controlled trial
Journal: BMJ (2013)

have alerted us to an error in the paragraph "Sample size."The second sentence should have read: "To have 80% power to detect a difference in mean BMI of 0.38 [not "0.25"] units between the groups at age 2 at the two sided 5% significance level, we needed a sample size of 252 per group."The incorrectly published value of 0.25 is, in fact, the calculation for the BMI z score (SD 1.0).BMI z scores were compiled (reported at www.bmj.com/content/344/bmj.e3732/rr/594950) but not stated in the published paper as BMI was identified as the best measure of change in adiposity.In addition, the data collection was all at 24 months; therefore an adjustment of age (with BMI z score) became unnecessary.This correction has no effect on the results.
ALPHÉE CAZENAVE (1795-1877)
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Early care for the heart attack suspects
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fatigue and Efficiency.
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
Journal: BMJ (2011)

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trialsThe abstract of this research paper by Rémy Boussageon and colleagues (BMJ 2011;343:d4169
Intraocular Pressure in Electroconvulsive Therapy
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018.
Authors: Philippa Gail Corrie, Lawton Sarah, Rebecca Smittenaar, Ruth Board
Journal: Journal of Clinical Oncology (2020)

e19310 Background: Population-based research provides real world information about prescribing trends, as well as benefits and harms associated with new interventions first evaluated in randomized clinical trials (RCTs). The national health service in England collects data on systemic anti-cancer therapy (SACT) prescribed to patients. We retrospectively examined outcomes including overall survival (OS) and treatment toxicity for patients (pts) prescribed checkpoint inhibitors (CPIs) approved for 1 st line use in metastatic melanoma. Methods: National Cancer Registration and Analysis Service (NCRAS) datasets were used to identify metastatic melanoma pts prescribed 1 st line CPIs and calculate survival outcomes. The Hospital Episode Statistics database was used to identify emergency department attendances and emergency hospital admissions. Results: Between April 2014 and March 2018, 5,465 melanoma pts were prescribed SACT. Of these, 2,322 pts received 1 st line CPIs for metastatic disease at 56 different hospitals in England: 1,174 were prescribed pembrolizumab (pembro), 724 ipilimumab (ipi), 52 nivolumab (nivo), 372 ipinivo. Prescribing reflected national access, starting with ipi in July 2014, replaced by pembro in Nov 2015 and ipinivo prescriptions started in July 2016. By 2018, 1 in 3 pts were receiving ipinivo as treatment of choice. There was high concordance for 3yr OS with RCT outcomes for ipi (32%) and ipinivo (58%), but pembro outcomes were poorer (40%). Pts prescribed pembro were significantly older (51% vs. 12% &gt;70 years) and frailer (38% vs. 61% ECOG PS 0) than pts prescribed ipinivo (p&lt;0.0001). 30-day rates of emergency hospital attendances/admissions from the earliest SACT and last SACT treatment dates were significantly higher for ipinivo (16%/37% and 19%/55%) compared with pembro (8%/17% and 14%/29%). Colitis was the most common IrAE associated with hospitalization: 25% with ipinivo and 4% with pembro. 30-day mortality from last SACT was 3.8% with ipinivo and 9.1% with pembro (p&lt;0.0001). Conclusions: Linked real world datasets demonstrated OS outcomes remarkably similar to RCTs associated with ipi and ipinivo, while poorer outcomes associated with pembro may reflect patient selection bias. Ipinivo generated the highest rates of emergency hospital visits and admissions, but 30-day mortality was not compromised, potentially reflecting efficient and effective management of complications. Hospital-level outcomes and 30-day mortality causes are now being assessed to explore variations in care.
Correction
Authors: B Chir, -Nb Christopher, B Greenwood, C Williamson, D Allan, J Goonon, D Holland, -Pa Greer, A Smith, M Colmer, R Curtis, John Mckenzie, Christopher Andrewes, C Wilson, J Young, W Eastham, J Anderson, S Bisary3, Nisa Fakhar-Un-, J Chaury, S Fryatt, M Irfan, W Jarallah, V Khalidi, Anita Lakshmi, A Mathias, J Cavanagh, J Malins, Mr Bevan
Journal: BMJ (1963)
"LONG-TERM EFFICACY OF TIOTROPIUM IN RELATION TO SMOKING STATUS IN THE UPLIFT TRIAL". D.P. TASHKIN, B. CELLI, S. KESTEN, T. LYSTIG, S. MEHRA AND M. DECRAMER. EUR RESPIR J 2010; 35: 287-294.
Journal: European Respiratory Journal (2010)

The authors have noticed some minor discrepancies in the above manuscript about which they wish to notify readers.As part of a sensitivity analysis during the review process, the efficacy end-points were re-analysed, adjusting for baseline maintenance respiratory medication use.The re-analysis led to extremely minor difference in numbers, without in any way altering whether the results were nominally statistically significant or the interpretations of the findings.All relevant areas were updated accordingly prior to publication.However, parts of the abstract and of table 3 were not adjusted.In the abstract, the third paragraph should have appeared as follows:''60%, 14% and 26% of patients were CE, CS and IS, respectively.The rate of forced expiratory volume in 1 s (FEV1) decline for placebo patients was most rapid in CS (-52¡4, -37¡2 and -23¡2 mL?yr -1 in CS, IS, and CE, respectively).Tiotropium did not alter FEV1 decline, but was associated with significant improvements in pre-and post-bronchodilator FEV1 over placebo that persisted throughout the 4-yr trial for each smoking status (pre-bronchodilator: 127, 55 and 97 mL at 48 months in CS, IS and CE, respectively; pf0.0003).Tiotropium reduced the exacerbation risk in CS (HR (95% CI) 0.80 (0.67-0.95)), in CE (0.85 (0.79-0.92)) and trended towards significance in IS (0.89 (0.79-1.00)).At 4 yrs, St George's Respiratory Questionnaire for tiotropium patients improved the most in CS (-4.63 units, p50.0006) and the least in IS (-0.60 units, p50.51), compared with control.''The treatment differences in table 3 were rounded to the nearest mL.The table should have appeared as below, with appropriate adjustments to the last column of data.
Complex Mixtures of Air Pollutants: Characterizing the Cancer Risk of Polycyclic Organic Matter
Authors: Joellen Lewtas
Journal: Environmental Health Perspectives (1993)

Complex mixtures of polycyclic organic matter (POM) are used to illustrate the scientific problems and issues associated with characterizing the comparative risk of related complex mixtures. The complexity of mixtures in which the active components are not well characterized present special challenges, which include identifying the critical components of mixtures, their sources, and the appropriate biomarker(s) of exposure and dose; developing the appropriate experimental models for dose-response assessment; species extrapolation; and developing a scientific basis for predicting from one mixture to another. Strategies for addressing these issues include bioassay-directed chemical characterization of bioactive components of complex mixtures, apportionment methods to determine the source of biological activity and risk, DNA adduct methods to determine tissue exposure and target dose of mixtures, and comparative approaches to determining the relative similarity, potency, and risk of complex mixtures. Epidemiological data are available for humans exposed to POM from coke ovens, coal roofing tar, coal smoke, aluminum smelters, and cigarette smoke. These emissions are characterized and compared to POM from automotive emissions (diesel and gasoline), woodstove emissions, residential oil furnace emissions, and ambient air particles. The tumor potency and estimated cancer risks for these POM mixtures ranges over nearly three orders of magnitude.